Search
losmapimod
Contraindications:
- myocardial infarction
Mechanism of action:
- inhibits p38MAPKs
- reduces serum C-reactive protein & serum pro-BNP at 4 weeks after myocardial infarction,
- does not reduce a composite outcome of cardiovascular death, MI, or recurrent ischemia evascularization at 12 weeks relative to placebo (8.1% vs 7.0%)
Related
SB203580
General
anti-inflammatory agent
protein kinase inhibitor
References
- O'Donoghue ML et al.
Effect of losmapimod on cardiovascular outcomes in patients
hospitalized with acute myocardial infarction: A randomized
clinical trial.
JAMA 2016 Apr 4
PMID: 27043082